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ABSTRACT
Objectives: To characterise the costs to the UK
National Health Service of cardiovascular (CV) events
among individuals receiving lipid-modifying therapy.
Design: Retrospective cohort study using Clinical
Practice Research Datalink records from 2006 to 2012
to identify individuals with their first and second CV-
related hospitalisations (first event and second event
cohorts). Within-person differences were used to
estimate CV-related outcomes.
Setting: Patients in the UK who had their first CV
event between January 2006 and March 2012.
Participants: Patients ≥18 years who had a CV event
and received at least 2 lipid-modifying therapy
prescriptions within 180 days beforehand.
Primary and secondary outcome measures:
Direct medical costs (2014 £) were estimated in 3
periods: baseline (pre-event), acute (6 months
afterwards) and long-term (subsequent 30 months).
Primary outcomes included incremental costs, resource
usage and total costs per period.
Results: There were 24 093 patients in the first event
cohort of whom 5274 were included in the second event
cohort. The mean incremental acute CV event costs for
the first event and second event cohorts were: coronary
artery bypass graft/percutaneous transluminal coronary
angioplasty (CABG/PTCA) £5635 and £5823, myocardial
infarction £4275 and £4301, ischaemic stroke £3512 and
£4572, heart failure £2444 and £3461, unstable angina
£2179 and £2489 and transient ischaemic attack £1537
and £1814. The mean incremental long-term costs were:
heart failure £848 and £2829, myocardial infarction £922
and £1385, ischaemic stroke £973 and £682, transient
ischaemic attack £705 and £1692, unstable angina £328
and £677, and CABG/PTCA £−368 and £599.
Hospitalisation accounted for 95% of acute and 61% of
long-term incremental costs. Higher comorbidity was
associated with higher long-term costs.
Conclusions: Revascularisation and myocardial
infarction were associated with the highest incremental
costs following a CV event. On the basis of real-world
data, the economic burden of CV events in the UK is
substantial, particularly among those with greater
comorbidity burden.
INTRODUCTION
Cardiovascular (CV) disease is a major cause
of premature death worldwide and an
important source of disability. Elevated levels
of blood lipids represent a major risk factor
for the development of coronary heart
disease including myocardial infarction (MI)
and angina, as well as other CV events
including stroke, transient ischaemic attack
(TIA) and peripheral arterial disease. A
history of these events places individuals at
higher risk of experiencing subsequent CV
events.1
A meta-analysis of 21 trials of >170 000 ran-
domised patients demonstrated that the inci-
dence of major CV events was reduced by
∼25% for each mmol/L reduction in low-
density lipoprotein (LDL) cholesterol.2
Therefore, reducing serum cholesterol levels
is the cornerstone of CV disease prevention
efforts.3 Drug treatment with lipid-modifying
therapy to lower lipids, especially statins, is
commonly used with the goal of reducing
population CV event rates. In addition to the
potential public health beneﬁts, lower CV
event rates from reducing LDL should also
have economic beneﬁts in terms of cost
Strengths and limitations of this study
▪ All estimates were calculated using real-world
data for the UK.
▪ Incremental costs were estimated using within-
person differences to minimise confounding.
▪ All patients received lipid-modifying therapy,
maximising the relevance for this population.
▪ Censoring in the data may affect the cost esti-
mates, particularly for long-term costs.
▪ The estimates were based on external cost data
applied to general practitioner and inpatient hos-
pitalisation usage, with limited information on
outpatient specialist care.
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offsets from prevented CV events. However, many
patients do not attain target lipid levels for a variety of
reasons including the use of lower than optimal doses,
non-compliance and very high levels of LDL that cannot
be sufﬁciently lowered with existing therapies. Thus,
these individuals carry a higher risk of CV events such as
MI and stroke that could be reduced with greater LDL
reductions and/or improved adherence.1 3
In the UK, studies of the cost of CV events have not
been conducted until now, which is most likely due to
two challenges. First, cost information is generally not
included with clinical data in the UK. Therefore, analys-
ing costs requires a complicated process of merging
information from disparate sources. Second, the linkage
to Hospital Episode Statistics (HES) data has relatively
recently become available to provide the detailed infor-
mation necessary for estimating costs based on
Healthcare Resource Groups (HRGs).
Until now, CV event cost estimates have been based pri-
marily on expert opinion regarding usage, combined
with UK-speciﬁc costs for the resources.4 Although
studies of CV event costs have been previously published,
they are generally limited to analysing short-term costs
using US data sources.5–10 While these studies include
patients receiving lipid-modifying therapy, they tend to
focus on patients hospitalised for CV events, or patients
with atherosclerosis, hypertension or acute coronary syn-
drome; they do not provide estimates speciﬁc to the lipid-
modifying therapy population which may experience a
different distribution of CV events with different patterns
of resource use. Having analyses in the lipid-modifying
therapy population provides useful evidence to physi-
cians, payers or other decision-makers interested in the
burden of CVD and related health economic analyses.
The present study was designed to provide evidence-
based estimates of healthcare resource use (HRU) and
costs speciﬁcally for the lipid-modifying therapy popula-
tion. The primary objective was to estimate the short-
term and long-term HRU and costs associated with spe-
ciﬁc new CV events (including initial and subsequent
events) in UK patients receiving lipid-modifying therapy.
A secondary objective was to explore the effects of
comorbidity burden on these costs.
METHODS
Study overview
This was a retrospective cohort study to estimate
resource usage and direct medical costs after surviving a
ﬁrst or second CV event in patients receiving lipid-
modifying therapy prior to the event. Primary care data
were obtained from electronic medical records in the
Clinical Practice Research Datalink (CPRD), and
inpatient data were obtained from the linked HES data.
Data sources
This was an observational cohort study.11 The CPRD
contains anonymised information from general
practitioners (GP) on demographics, symptoms, diagno-
ses, test results and referrals to secondary care, and is a
widely used database globally.12 These patients are
broadly representative of the UK general population in
terms of age, sex and ethnicity. At the time this study
was conducted, the CPRD-HES linkage included hospita-
lised care but did not include data for outpatients or for
accident and emergency visits.
Patient populations
The study population included adult patients
(≥18 years) who were alive and observable in the CPRD
and HES data as of 1 January 2005, and were hospita-
lised for their ﬁrst CV event between January 2006 and
31 March 2012 (end of HES observation period). Only
patients who had a CV event in the HES data were
included in the study. CV events were deﬁned as hospita-
lisations with a primary International Classiﬁcation of
Diseases, 10th Revision (ICD-10) diagnosis code for MI,
ischaemic stroke (IS), heart failure (HF), TIA or
unstable angina (UA), or other hospitalisations for revas-
cularisation that included coronary artery bypass graft
(CABG) or percutaneous transluminal coronary angio-
plasty (PTCA). Percutaneous coronary intervention
(angioplasty with stenting) was included with PTCA.
Patients with a history of an acute event (MI or IS) in
the CPRD data before 2006 were also excluded.
Prescription records for lipid-modifying therapy were
used to identify patients receiving treatment to reduce
serum lipid levels. To ensure that patients were receiving
lipid-modifying therapy prior to their ﬁrst CV event, they
had to have received at least two prescriptions for lipid-
modifying therapy in the 180 days prior to the index
date. Lipid-modifying therapy included statins, ezeti-
mibe, ﬁbrates, nicotinic acid and bile acid sequestrants.
The date of the event that qualiﬁed the patient to be
in a cohort was deﬁned as the ‘index’ date. To rule out
previous events more accurately, patients were required
to have at least 12 months of data prior to the CV event
date; we also required at least 30 days of follow-up after-
wards to properly categorise the index event. Patients
who met these inclusion criteria were included in the
ﬁrst event cohort. In addition, a second event cohort
was created using patients who had a subsequent CV
event, the date of which was their index date (see online
supplementary materials ﬁgure S1).
The medical history of any of the following conditions
in the CPRD was also captured: diabetes, peripheral
artery (vascular) disease, abdominal aortic aneurysm,
TIA, ischaemic heart disease (excluding MI or UA),
carotid artery disease or angina pectoris. These condi-
tions were identiﬁed using READ codes based on code
lists from the Quality Outcomes Framework (QOF)
where possible.13
Study design
This was a pre–post design, using patients as their own
controls, and was used to reduce the inﬂuence of
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potential confounders that could have inﬂuenced the
CV event costs. Patients were selected at the time they
had their qualifying CV event. To estimate costs related
to ﬁrst and second CV events compared with no CV
event, we estimated costs after each CV event and calcu-
lated the incremental difference from the period before
the ﬁrst CV event.
The assessment of demographics and comorbidity
information was based on information present at the
time of the index CV event. Baseline usage and costs for
all cohorts were estimated during the 12-month period
prior to the ﬁrst CV event for all patients. The follow-up
period for the assessment of HRU and costs started with
the date of the index CV event and continued for
36 months, or until the end of data availability within
the HES database (31 March 2012). Patients were also
censored at date of death, date of a subsequent CV hos-
pitalisation event, date of last known up-to-standard
CPRD record for the patient in the practice or 31 March
2012, whichever came ﬁrst.
For the subset of ﬁrst event cohort patients who had a
second CV event, the baseline period was the 12-month
period before the second event and the follow-up
period was the 36-month period after it. Since follow-up
was censored at subsequent CV events, costs were not
double-counted between the ﬁrst event and second
event cohorts. This facilitated reporting costs for ﬁrst
and second events separately as well as reporting pooled
results.
The primary time periods for the analyses were the
ﬁrst 6 months after the index event (‘acute period’),
and the subsequent 30 months after the acute period
(‘long-term period’). These intervals were selected to
align with time frames provided in a National Institute
for Health and Care Excellence (NICE) clinical guide-
line for lipid modiﬁcation.4 Long-term outcomes were
annualised for easier interpretation. For analyses of
incremental usage and cost in this cohort, the 12-month
period before the ﬁrst CV event was used as the baseline
for calculating all cost differences, including those in
the second event cohort. This was done to have a con-
sistent reference cost for the calculation of incremental
costs across cohorts.
Study end points
Primary end points
The primary end points in this study were resource usage
and direct medical costs for the acute period after a CV
hospitalisation, and the subsequent long-term period.
Both total and incremental CV-related costs were esti-
mated, including hospitalisations (HES), outpatient refer-
rals (CPRD), primary care ofﬁce visits (CPRD) and
medications (CPRD). Medications included lipid-lowering
therapy, antihypertensive therapy, antithrombotic therapy
and antidiabetic therapy (see online supplementary mate-
rials table S1).
All events within 30 days after the initial event were
used to categorise the event type. Multiple events
occurring within this 30-day window were assigned to a
group using the highest event from the following hier-
archy: MI, UA, IS, CABG, PTCA, HF and TIA. (For
example, someone with a TIA followed by MI, then
CABG within a 30-day window would be assigned to the
MI group.) This ensured that temporally close observa-
tions were not double-counted, and reduced censoring
due to subsequent events. All hospitalisations were iden-
tiﬁed using ICD-10 codes for diagnoses and Ofﬁce of
Population, Censuses and Surveys (OPCS) codes for pro-
cedures (see online supplementary materials table S2).
Costing
Data sources
Unit costs were attributed to the identiﬁed resource
use category for each individual patient and aggre-
gated across all patients. Unit costs for secondary care
(hospitalisation) and drugs were derived from the
2014 UK National Health Service (NHS) sources to
ensure transparency and relevancy in the source of
cost data.14 15 Primary care unit costs were estimated
from the Personal Social Services Research Unit 2014
costs.16
Ofﬁce visits in surgery or clinic were priced at £46
(11.7 min visit) and telephone consultations at £28
(7.1 min consult) based on 2014 data.15 Outpatient
referrals listed in the CPRD data were assumed to have
occurred and costs were assigned using NHS reference
costs for 2013–2014 according to specialty type.4 Costs
for hospitalisations were based on HRG Reference Costs
and were assigned using the 2013/2014 HRG4+
Reference Costs Grouper software.14 All available diag-
nosis and procedure codes were used to assign the hos-
pital cost. Drug costs were based on the NHS Electronic
Drug Tariff for England and Wales using data from
September 2014 where possible, augmented with other
months in 2014 for drugs that did not have a September
2014 cost. Generic prices were used where possible.17
Analyses
Estimation of patient costs was performed by multiplying
the quantity of each resource used by the corresponding
unit cost of the resource. Costs were grouped into hos-
pital, drug and ofﬁce visit (including outpatient refer-
ral). Acute and long-term incremental and total costs
were also stratiﬁed by the type of index event.
Exploratory analyses of acute and long-term incremental
costs were stratiﬁed by the Charlson Comorbidity
Index18 and by age group. Comorbid conditions for the
Charlson Comorbidity Index were identiﬁed using a
study that provided UK-speciﬁc code lists for each
condition.19
Since patients were censored during the follow-up
period, we used inverse probability weighting to account
for censoring and death.20 21 This facilitated the summa-
tion of costs, and the calculation of incremental costs
over the time intervals in the study, even when different
numbers of patients were present in each interval.
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To combine costs and align with the acute and long-
term periods, the ﬁrst year costs were divided into two
6-month time intervals, while the remaining costs were
divided into annual time intervals. Death was treated as
a censoring event to align with economic model inputs
that require the annual cost of care for survivors
(ie, attenuation of costs due to death is incorporated
into the economic models22). Variances were estimated
using bootstrapping of the inverse probability weighted
estimates for each time interval. Usage estimates were
analysed similarly to cost estimates to account for censor-
ing and death.
Patient demographic and clinical characteristics were
described using means and SDs for continuous variables,
and percentages for categorical variables. Analyses of
mortality rates were based on deaths from all causes
divided by person-years of follow-up until death or a cen-
soring event, and are expressed per 100 person-years. All
analyses were conducted in R (V.3.1.3).23
RESULTS
Cohort overview
Baseline characteristics and mortality rates are sum-
marised by cohort in table 1. There were 24 093 patients
in the ﬁrst event cohort. Of these, 5274 (22%) had a
subsequent CV event in our study time horizon and
were also included in the second event cohort. The
mean age at the time of their CV event was 73 years in
both cohorts, the proportion of males was 59% and 60%
respectively, the mean body mass index was 29 kg/m2 in
both cohorts, and baseline LDL cholesterol levels were
2.3 and 2.2 mmol/L, respectively. Within 6 months of
the index event, 11.5% of the ﬁrst event and 13.9% of
the second event cohort died. All-cause mortality rates
were higher in the 6-month acute period (28.5 and 36.5
per 100 person-years, respectively), and lower in the
30-month long-term period (5.4 and 6.2 per 100 person-
years, respectively). Figure 1 shows the distribution of
CV event type for each of the cohorts. Approximately
97% of patients were included in the study based on
receiving a statin as their lipid-modifying therapy pre-
scription within 180 days prior to their ﬁrst CV event
(table 1).
CV event costs
The incremental CV event costs in the acute period were
£3504 in the ﬁrst event cohort and £3968 in the second
event cohort (table 2). The incremental cost for both
cohorts combined was £3577. Hospitalisation costs were
£3338 and £3737, respectively, and £3400 averaged
across both cohorts. The incremental costs in the subse-
quent 30 months were £361 and £1018 per year, respect-
ively, and £439 averaged across both cohorts.
Hospitalisation accounted for 95% of acute and 61% of
long-term incremental costs.
In terms of index event subgroups, the highest acute
period incremental CV event costs were for the CABG/
PTCA, MI and patients with IS in both cohorts (table 2).
The mean costs for the ﬁrst event and second event
cohorts were as follows: CABG/PTCA £5635 and £5823,
MI £4275 and £4301, IS £3512 and £4572, HF £2444 and
£3461, UA £2179 and £2489 and TIA £1537 and £1814.
The subsequent long-term incremental costs (per year)
were more heterogeneous and were as follows for the
ﬁrst event and second event cohorts, respectively: HF
£8848 and £2829, MI £922 and £1385, IS £973 and £682,
TIA £705 and £1692, UA £328 and £677, and CABG/
PTCA £−368 and £599.
Figure 2 shows stratiﬁed incremental costs for each
cohort by comorbidity status, and table 3 shows the cor-
responding rate of ofﬁce visits, subsequent CV event
rate, death rate and the initial CV hospitalisation length
of stay. In the ﬁrst event cohort, higher comorbidity
scores from the Charlson Comorbidity Index were asso-
ciated with comparable acute period costs and higher
long-term period costs. In the second event cohort,
acute and long-term annual costs increased with the
Charlson score. These trends were generally mirrored by
corresponding usage and event rate patterns in table 3.
Costs stratiﬁed by age group did not vary as systematic-
ally (see online supplementary materials ﬁgure S2).
Overall and hospital-speciﬁc total (ie, non-
incremental) costs in the 12-month baseline period, the
6-month acute period and the 30-month long-term
period are provided in table 2. In terms of total costs
within the baseline period, the highest was for patients
with HF, whose annual cost was £3149 in the ﬁrst event
cohort and £2738 in the second event cohort. In the
acute period, the highest total cost was for CABG/
PTCA, which was £6843 in the ﬁrst event cohort and
£6630 in the second event cohort. In the long-term
period, the highest annualised cost was in patients with
HF, which was £3608 in the ﬁrst event cohort and £5554
in the second event cohort.
In the acute period after the index event, there were
5.0 and 6.1 more ofﬁce visits as well as 1.5 and 1.6 more
non-CV hospitalisations per person and 1 CV hospitalisa-
tion per person for the ﬁrst event and second event
cohorts, respectively. During the long-term period after-
wards, there were 2.9 and 4.8 more ofﬁce visits as well as
0.2 and 0.5 more non-CV hospitalisations compared with
the baseline period. The mean length of stay for the
index hospitalisation was shortest for UA (4.5 and
4.9 days) and longest for IS (22.5 and 26.7 days).
DISCUSSION
Estimating resource use and the associated costs of man-
aging CVD is important for estimating the value of inter-
ventions that reduce the risk of CV events. Until now,
these estimates have been based on expert opinion
regarding usage, combined with UK-speciﬁc costs for
the resources.12 To the best of our knowledge, this is the
ﬁrst study both to measure usage in lipid-modifying
therapy patients with CV events using comprehensive
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real-world data and to combine this information with
costs from the UK perspective.
These data show that the cost of care for patients
experiencing a CV event was generally very high in the
acute period following the event. In particular, patients
with a second CV event had higher incremental
CV-related costs. These incremental CV-related costs
were generally much smaller in the long-term period,
although they were almost always still positive (ie,
greater than the baseline pre-CV event period). The
Table 1 Baseline characteristics
Cohort
Variable First event (n=24 093) Second event (n=5274)
Continuous variables N Mean SD N Mean SD
Age at index 24 093 72.7 11.1 5274 72.8 10.8
BMI 15 005 28.8 5.7 3457 28.7 5.6
SBP 23 107 136.1 19.2 5119 132.6 20.1
LDL cholesterol 13 247 2.4 2.3 2803 2.2 0.9
Total cholesterol 19 693 4.4 1.4 4267 4.2 1.4
Triglycerides 15 064 1.6 1.2 3143 1.6 1.0
Categorical variables Level N Per cent N Per cent
Lipid-modifying therapy (before or on index date)* Low-dose statin 1918 8.0 428 8.1
Moderate-dose statin 18 556 77.0 3980 75.5
High-dose statin 2886 12.0 695 13.2
Ezetimibe 465 1.9 104 2.0
All others 268 1.1 67 1.3
Year of index event 2006 3948 16.4 425 8.1
2007 3975 16.5 782 14.8
2008 3858 16.0 877 16.6
2009 4023 16.7 986 18.7
2010 3801 15.8 980 18.6
2011 3630 15.1 987 18.7
2012 858 3.6 237 4.5
Age group <60 3170 13.2 652 12.4
60–69 4892 20.3 1007 19.1
70–79 8864 36.8 2092 39.7
≥80 7167 29.8 1523 28.9
Gender Male 14 221 59.0 3177 60.3
Female 9872 41.0 2097 39.8
Smoking status Current 2867 11.9 488 9.3
Former 9020 37.4 2248 42.6
Never 6483 26.9 1375 26.1
Charlson Comorbidity Index (score) None 7199 29.9 831 15.8
One 5378 22.3 1029 19.5
Two or higher 11 516 47.8 3414 64.7
Risk factors Hypertension 10 291 42.7 2364 44.8
Diabetes 7343 30.5 1905 36.1
COPD 1958 8.1 524 9.9
CKD 6038 25.1 1815 34.4
AF 3085 12.8 1014 19.2
CV conditions AAA 143 0.6 25 0.5
Angina 7239 30.1 1861 35.3
PVD 1972 8.2 524 9.9
TIA 2005 8.3 442 8.4
Cardiac ischaemia 10 261 42.6 2508 47.6
Carotid stenosis 223 0.9 54 1.02
Other medications Antihypertensive 20 973 87.1 4979 94.4
Antithrombotic 18 818 78.1 4901 92.9
Antidiabetic 6073 25.2 1599 30.3
Mortality rate (per 100 person-years) Time interval Person years Died Rate Person years Died Rate
Acute 0–6 months 9686 2764 28.5 2006 733 36.5
Long term 7–36 months 22 798 1240 5.4 3967 246 6.2
*Lipid-modifying therapy refers to the closest prescription to the index date within 180 days prior to it. See online supplementary materials for
definitions of medication categories.
AAA, abdominal aortic aneurysm; AF, arterial fibrillation; BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; CV, cardiovascular; LDL, low-density lipoprotein; PVD, peripheral vascular disease; SBP, systolic blood pressure; TIA,
transient ischaemic attack.
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exception to this trend was for CABG/PTCA in the ﬁrst
event cohort, which suggests that this procedure might
have long-term cost offsets in patients who had these
procedures in the absence of one of the other qualifying
CV events. The incremental long-term cost in the
second event cohort was the lowest in patients with
CABG/PTCA.
It is also interesting that the ﬁrst event and second
event cohorts often had similar incremental acute
CV-related costs. This is most likely related to hospitalisa-
tion costs, which were the dominant cost driver during
our study’s time horizon. In addition, it appears that
comorbidity burden is an important contributor to
incremental long-term costs as shown in ﬁgure 2. The
modest association of age and long-term costs in online
supplementary materials ﬁgure S2 is most likely caused
by increases in comorbidity burden with increasing age
in the three younger age groups. We were not able to
evaluate the effects of compliance and persistence with
lipid-modifying therapy on clinical and economic out-
comes. However, a recent study showed that 43% of
patients discontinued their statins within 12 months of
initiation, highlighting the importance of doing such
research in the future.24
It is important to highlight the clinical implications of
these results. CV events are multifactorial, and CV event
costs might vary according to the CV risk factors of the
patient population. Since our focus was on estimating
costs in patients at risk of atherosclerotic vascular events,
we required patients to have received at least two lipid-
modifying therapy prescriptions within 180 days. While
one would expect CV event costs to be similar in other
populations, these results are most relevant for patients
receiving lipid-modifying therapy. The fact that many of
these patients, most of whom were receiving antithrom-
botic and antihypertensive treatment, went on to experi-
ence subsequent CV events highlights the limitations of
available interventions in a population with substantial
need. Furthermore, the progressively more costly results
by higher comorbidity risk score indicate that comorbid
conditions are another important factor for these
patients.
The primary value of these analyses is that they are
derived from current real-world data in the UK. The
CPRD data reﬂect the medical records of ∼6% of all
patients in clinical practice in the UK, and are considered
to be a very reliable source of longitudinal patient data,
supporting over 1500 publications.25 26 Patients were
included based on hospitalisations in the HES data, so
they align with intense resource usage that is relevant to
supporting economic modelling efforts. This is in con-
trast to events recorded in the CPRD GP data that may
not reﬂect hospitalisation, depending on the reason for
recording a diagnosis code at a particular ofﬁce visit.27
Finally, the perspective of the NHS was used for costing
where possible, to ensure alignment with the payer for
the majority of services provided in the UK.
It must be emphasised, though, that our ﬁndings
merit careful interpretation in the light of potential lim-
itations of our data and the analyses. For instance, we
used external data sources for 2014 for costing and
these may not reﬂect the actual resources used for the
patients in this study. This is most likely to affect the hos-
pitalisation costs, since the costs of ofﬁce visits and drugs
are much smaller and less variable. We included the cost
of referral visits, based on referrals recorded in the
CPRD referral ﬁle. We cannot ascertain whether these
visits actually occurred, so the usage of these services
(and hence the costs) may be overestimated. On the
contrary, not every visit to a specialist is recorded by the
GP, causing cost underestimation and counterbalancing
the potential bias to some degree.
Importantly, we included all hospitalisations for each
patient in our usage and cost analyses, and not just CV
hospitalisations. This may lead to more noise in the data
if there were to be no relationship between the CV events
Figure 1 Distribution of types of
index events by cohort. CABG,
coronary artery bypass graft; HF,
heart failure; IS, ischaemic stroke;
MI, myocardial infarction; PTCA,
percutaneous transluminal
coronary angioplasty; TIA,
transient ischaemic attack; UA,
unstable angina.
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Table 2 CV event-related costs by cohort and index event
Cohort Group n
Total costs (in £) Incremental total costs (in £)
Baseline (1 year
before first CV event)
(mean (SE))
Months 1–6
(mean (SE))
Months 7–36
annualised
(mean (SE))
Months 1–6
(mean (SE))
Months 7–36
annualised (mean (SE))
First event Myocardial infarction 4468 2266.34 (163.45) 5297.59 (115.51) 2350.66 (165.54) 4275.41 (102.41) 922.43 (155.58)
Unstable angina 5801 1965.61 (86.76) 3133.12 (61.44) 2081.84 (65.15) 2179.24 (48.51) 328.45 (61)
Ischaemic stroke 3489 1962.42 (119.73) 4389.27 (102.29) 2526.63 (276.42) 3512.25 (102.82) 972.62 (257.48)
PTCA/CABG* 5082 2412.2 (95.69) 6843.38 (94.67) 1855.11 (110.02) 5635.19 (87.29) −368.26 (103.58)
Heart failure 3596 3148.72 (136.77) 3988.86 (111.87) 3607.86 (313.16) 2443.58 (95.22) 847.55 (247.64)
Transient ischaemic attack 1657 2109.76 (215.46) 2488.83 (89.42) 2362.10 (152.91) 1536.88 (69.22) 704.76 (147.47)
All patients (hospital) 24 093 1565.41 (56.72) 4059.91 (38.39) 1432.92 (59.15) 3337.51 (37.75) 203.18 (48.2)
All patients (total) 24 093 2301.34 (57.26) 4594.16 (39.01) 2262.92 (60.37) 3504.01 (38.04) 361.11 (48.79)
Second event Myocardial infarction 769 2611.88 (326.29) 5785.47 (353.52) 3887.74 (909.42) 4301.01 (330.02) 1384.51 (622.14)
Unstable angina 1347 2795.44 (398.16) 3925.66 (204.31) 2844.49 (247.33) 2489.48 (132.63) 676.82 (278.78)
Ischaemic stroke 532 2202.96 (143.98) 5607.47 (273.97) 2870.35 (281.51) 4572.28 (280.27) 682.29 (438.78)
PTCA/CABG* 1256 1635.76 (63.68) 6630.29 (208.77) 2121.06 (302.87) 5823.12 (202.55) 598.64 (296.25)
Heart failure 1104 2737.60 (97.24) 4818.24 (318.44) 5554.17 (1732.62) 3460.91 (312.14) 2829.02 (1643.39)
Transient ischaemic attack 266 1999.77 (142.44) 2734.81 (183.68) 3337.07 (814.53) 1813.63 (187.64) 1691.81 (790.76)
All patients (hospital) 5274 1588.26 (100.82) 4530.08 (100.6) 2061.65 (237.53) 3736.68 (85.06) 762.21 (237.68)
All patients (total) 5274 2380.42 (100.97) 5147.79 (100.62) 2998.11 (242.14) 3967.74 (84.73) 1017.68 (239.47)
First and second
events combined
Myocardial infarction 5237 2317.12 (144.72) 5354.01 (113.64) 2472.28 (168.56) 4277.23 (95.51) 958.78 (134.53)
Unstable angina 7148 2121.98 (111.68) 3261.27 (65.83) 2179.64 (75.16) 2229.42 (50.81) 373.15 (74.47)
Ischaemic stroke 4021 1994.31 (91.59) 4533.08 (103.14) 2545.1 (274.62) 3637.86 (103.05) 953.48 (261.93)
PTCA/CABG* 6338 2258.28 (69.8) 6802.98 (86.73) 1894.5 (89.56) 5669.47 (85.13) −220.73 (83.14)
Heart failure 4700 3052.04 (112.99) 4144.89 (116.03) 3881.8 (344.1) 2635.35 (105.35) 1128.86 (300.08)
Transient ischaemic attack 1923 2094.55 (195.16) 2519.75 (87.9) 2447.92 (150.36) 1571.55 (68.74) 792.85 (146.55)
All patients (hospital) 29 367 1569.51 (43.75) 4133.76 (40.95) 1508.48 (59.3) 3400.25 (35.58) 269.32 (53.9)
All patients (total) 29 367 2315.55 (43.78) 4681.04 (41.45) 2351.28 (59.09) 3576.82 (36.18) 438.89 (54)
*The proportions of revascularisation events that were CABG were 42% (2137/5082), 35% (442/1256) and 41% (2579/6338) for the first event, second event and all (combined) cohorts,
respectively.
CABG, coronary artery bypass graft; CV, cardiovascular; PTCA, percutaneous transluminal coronary angioplasty.
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and hospitalisations for other non-CV diseases. However,
we have minimised this with a pre–post design over a rela-
tively short period of 3 years, and by calculating incre-
mental costs. In terms of medications, we focused on
antithrombotic, antihypertensive and antidiabetic drugs,
which are likely to be important. We did not analyse every
prescription in the CPRD data due to the variety of
drugs, doses and prescriptions; therefore, the drug costs
may be underestimated. Drug costs are generally low, so
this is not likely to be a large bias. Also, if the initial CV
event led to additional resource usage for other reasons
(eg, incidentally discovered conditions), these would be
included in the incremental costs. Along these lines,
older patients may receive different care than younger
patients, so the incremental costs might vary by age.
Finally, we used inverse probability of censoring weights
to combine data across time periods to reduce the loss of
information about costs and the incremental cost of CV
events. However, information from patients who did not
survive, or who were censored, is still lost and is estimated
by using the data from the remaining patients in the study.
For patients censored due to the end of their data, the
missing data are likely to be missing at random and should
not introduce a substantial bias. However, for patients who
died or were censored due to a subsequent CV hospitalisa-
tion, the costs estimated in this study may underestimate
the actual cost of care over time if the patients who were
censored were higher cost patients. This may at least partly
explain the lower cost estimates in the oldest patients (see
online supplementary materials ﬁgure S2).
Overall, this analysis provides a real-world, evidence-
based analysis of the resources used, and the associated
costs, in managing CV events in the UK. The burden is
higher in higher risk patients. The results demonstrate
the substantial economic burden and unmet medical
need for patients with CV events in the UK, despite the
use of lipid-modifying therapies.
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Figure 2 Incremental costs (£)
by Charlson Comorbidity Index
score and cohort. Note: Costs in
2014 £ based on assignment of
unit costs to usage as described
in the Methods section. Patients
stratified by Charlson Comorbidity
Index score, which is a function of
the number of comorbid
conditions and their association
with mortality. Higher scores
indicate a higher mortality risk.
Table 3 Event rates by Charlson Comorbidity Index score and cohort
Comorbidity score 0 Comorbidity score 1 Comorbidity score 2+
Acute Long term Acute Long term Acute Long term
First event
CV hospitalisation LOS (mean days) 7.6 NA 9.6 NA 11.4 NA
Office visits (per person year) 23.2 18.1 26.6 22.9 31.8 29.7
CV event rate (per 100 person years) 23.4 6.0 23.4 9.5 28.8 12.2
Death rate (per 100 person years) 13.5 2.4 22.7 4.8 42.0 8.4
Second event
CV hospitalisation LOS (mean days) 6.5 NA 8.5 NA 11.1 NA
Office visits (per person year) 26.1 30.8 31.3 41.3 38.2 54.6
CV event rate (per 100 person years) 25.5 11.1 38.0 12.6 39.1 19.6
Death rate (per 100 person years) 8.7 1.4 24.3 3.3 48.6 9.2
CV, cardiovascular; LOS, length of stay; NA, not applicable.
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